Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

TNS Energo Voronezh reported for 6 months of 2024 by IFRS

8/29/24 VRSB

TNS Energy Kuban reported for 6 months of 2024 by IFRS

8/29/24 KBSB

TNS Energy Mari El reported for 6 months of 2024 by IFRS

8/29/24 MISB

TNS Energo Nizhny Novgorod reported for 6 months of 2024 by IFRS

8/29/24 NNSB

TNS Energy reported for 6 months of 2024 by IFRS

8/29/24 TNSE

TNS Energy Rostov-on-Don reported for 6 months of 2024 by IFRS

8/29/24 RTSB

Rusolovo reported for 6 months of 2024 by IFRS

8/29/24 ROLO

NTEK reported for 6 months of 2024 by IFRS

8/29/24 YAKG

Seligdar reported for 6 months of 2024 by IFRS

8/29/24 SELG

VseInstrument.ru reported for 6 months of 2024 by IFRS

8/29/24 VSEH